Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CD38 | P28907 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2570362 | 0.89 | TAAR1 (0.46) | SLC6A2SLC6A4SLC6A3LMNACYP3A4 | |
| Hydrochloric Acid SCHEMBL1421227 | 0.87 | HTT (0.48) | SLC6A2SLC6A4SLC6A3LMNACYP3A4 | |
| SCHEMBL17113747 | 0.84 | CYP3A4 (0.42) | CYP3A4TAAR1KDM4EKMT2A | |
| SCHEMBL31737601 | 0.82 | HDAC8 (0.48) | P2RX7HDAC8EIF2AK1CYP3A4CD38 | |
| SCHEMBL19524985 | 0.80 | TAAR1 (0.53) | P2RX7LMNACYP3A4CD38TAAR1 | |
| SCHEMBL13996926 | 0.79 | P2RX7 (0.42) | P2RX7HDAC8EIF2AK1CYP3A4CD38 | |
| SCHEMBL3935647 | 0.78 | HTT (0.57) | P2RX7HTTNPSR1TAAR1KDM4E | |
| SCHEMBL4926760 | 0.77 | MAPT (0.47) | P2RX7HDAC8EIF2AK1CYP3A4CD38 | |
| SCHEMBL5993038 | 0.77 | P2RX7 (0.44) | P2RX7HDAC8EIF2AK1CYP3A4CD38 | |
| SCHEMBL26028930 | 0.76 | MPO (0.45) | SLC6A2SLC6A4SLC6A3CYP3A4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023158769-A1 | PROCESSES FOR THE PREPARATION OF N-(1- METHYLCYCLOPROPYL)-2-(3 -PYRIDINYL)-2H- INDAZOLE-4-CARBOXAMIDE AND INTERMEDIATES THEREOF | FMC CORPORATION (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023158771-A1 | THE PREPARATION OF N-(1-METHYLCYCLOPROPYL)-2-(3-PYRIDINYL)-2H-INDAZOLE-4-CARBOXAMIDE AND INTERMEDIATES THEREOF | FMC CORPORATION (US) | 2023-08-24 | — | — | WO | disclosed |
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-7538141-B2 | Compounds for the treatment of diseases | PFIZER INC. | 2009-05-26 | — | — | US | disclosed |
| WO-2008152014-A2 | 3-HETROCYCLYLIDENE-INDOLINONE DERIVATIVES AS INHIBITORS OF SPECIFIC CELL CYCLE KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | disclosed |
| US-7459460-B2 | Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-7351742-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. (US) | 2008-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222331-A1 | NEW COMPOUNDS | CCNA1, CCNY, MKI67 | P2RX7 807/4885HDAC8 3040/4885EIF2AK1 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.